EverEx Secures 14.8 Billion KRW in Series B Funding

Accelerating Global Expansion and Advancing AI-Based Motion Analysis Technology

EverEx, a musculoskeletal digital healthcare company, announced on July 31 that it has successfully secured a Series B investment totaling 14.8 billion KRW. This achievement comes two years after its 8 billion KRW Series A investment in 2023.

EverX

This investment round was led by existing investor Premier Partners, with follow-on investments from other current investors such as Quad Asset Management and Hana Ventures. Four new institutions?Korea Development Bank, Korea Venture Investment, Korea SMEs and Startups Agency, and Japan's SBI Investment?also participated, once again demonstrating their confidence in EverEx's technology and global growth potential.

With this investment, EverEx plans to accelerate its core strategies, including expanding the market for its motion analysis and remote rehabilitation monitoring solutions, which are currently adopted by over 100 medical institutions in Korea and abroad, and developing next-generation models of its AI motion analysis technology. The company will also speed up the expansion of its sales network for the "EverEx Rehab" solution, which is already commercialized in the United States, and strengthen its global presence by entering the Asia-Pacific (APAC) markets, including Singapore and Japan.

EverEx is also pursuing strategies for the domestic market. To expand the real-world use of MORA Cure, which was recently designated as the first innovative medical device for musculoskeletal digital therapeutics in Korea, the company is working to strengthen distribution channels and integrate with hospital electronic medical record (EMR) systems. Through these efforts, EverEx aims to enhance the usability and accessibility of its solutions in clinical settings.

One of the key factors behind this successful investment round is EverEx's AI motion analysis model technology. The company's specialized model, trained on approximately 700,000 musculoskeletal data points, delivers high accuracy and stability in mobile environments, earning recognition for its leading technology in the global market. Recently, three research papers on video understanding and generation were accepted at ICCV 2025, a prestigious global conference in the field of computer vision.

Yoon Chan, CEO of EverEx, stated, "This Series B investment demonstrates the market's trust in EverEx's technology and global expansion potential, even in a challenging investment environment. We will continue to commercialize and advance our products so that personalized musculoskeletal rehabilitation can be applied to more patients."

He added, "The musculoskeletal disease market has significant growth potential, as digital healthcare technology can deliver substantial improvement. Based on our technology, which is the first of its kind in Korea and recognized worldwide, we aim to contribute to global healthcare innovation."

EverEx offers a variety of digital rehabilitation solutions under the MORA brand. Its main products include: ▲ AI-based musculoskeletal analysis software MORA Vu and MORA Fit ▲ MORA Care, a musculoskeletal health management solution for employees ▲ MORA Ex, a remote musculoskeletal rehabilitation exercise solution ▲ MORA Cure, a digital therapeutic device (DTx) for musculoskeletal diseases. The company continues to collaborate with government agencies, hospitals, and associations to commercialize these four core solutions.